September 13, 2019
US Merck’s Japan unit MSD K.K. said on September 12 that it filed on the same day a new drug application (NDA) in Japan for its novel non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine for the treatment of HIV-1 infection. The...read more